Combination of Empiriko’s chemosynthetic livers and Interchim’s innovative instrumentation and expertise in the field of liquid chromatography allows pharmaceutical scientists to predict metabolism patterns, pathways and profiles, while generating a complete spectrum of oxidative metabolites for specific drugs and reducing the time for each experiment from weeks to hours.
In addition, scientists and clinicians can quickly identify interactions involving metabolite attenuation and suppression, and assess the genotoxicity, drug-to-drug interactions and efficacy associated with adding a new drug to a patient’s drug regimen.
Interchim’s latest PuriFlash instruments feature a mass spectrometer that allows near real-time product separation and structural elucidation of purified compounds and is ideally suited to support Empiriko’s Biomimiks technology.
Empiriko, under the new agreement, will also provide input to Interchim with regard to the design of future instrumentation for ex-vivo studies geared toward personalized patient treatment. The company’s approach to drug testing will drive efficiencies and cost savings, helping pharmaceutical companies realize the next generation of discoveries.
Empiriko chief scientific officer Mukund Chorghade noted the company’s partnership with Interchim represents an important step forward for both companies.
"We are able to offer more comprehensive drug discovery and clinical research solutions and results. Together we will accelerate the delineation of metabolism profiles, enable prediction and scale-up of products and offer scientists a valuable tool for rapid separation and quantification of products. We look forward to working with Interchim to advance the boundaries of DMPK studies," Chorghade added.